Efficacy and safety of COVID-19 vaccination in patients with cirrhosis  

作　　者：Vladimir Ivashkin Albina Ismailova Ksenia Dmitrieva Roman Maslennikov Maria Zharkova Salekh Aliev Vyacheslav Bakhitov Vadim Marcinkevich 

机构地区：[1]Department of Internal Medicine,Gastroenterology and Hepatology,Sechenov University,Moscow 119435,Russia [2]Department of Internal Diseases,Consultative and Diagnostic Center№2 of Department of Health,Moscow 107764,Russia [3]Administration,Consultative and Diagnostic Center№2 of Department of Health,Moscow 107764,Russia [4]The First Hospital Surgery Department,Pirogov Russian National Research Medical University,Moscow 117997,Russia

出　　处：《World Journal of Hepatology》2022年第7期1470-1479,共10页世界肝病学杂志（英文版）（电子版）

摘　　要：BACKGROUND The clinical efficacy and safety of vaccination against novel coronavirus disease 2019(COVID-19)in patients with cirrhosis have not been evaluated yet.AIM To evaluate the clinical efficacy and safety of vaccination against COVID-19 in patients with cirrhosis.METHODS This was a retrospective cohort study of patients with cirrhosis.The first cohort included patients vaccinated with Gam-COVID-Vac(Sputnik V);the second one consisted of unvaccinated controls.RESULTS The study included 89 vaccinated patients and 148 unvaccinated ones.There were 4 cases of COVID-19 in the vaccinated group and 24 cases in the unvaccinated group(P=0.035).No severe cases of COVID-19 were revealed in the vaccinated group,while there were 12 ones in the unvaccinated group(P=0.012)with 10 deaths detected(P=0.012).The vaccine efficacy was 69.5%(95%confidence interval[CI]:18.5%-94.4%)against symptomatic cases of COVID-19,100%(95%CI:25.1%-100.0%)against severe cases,and 100%(95%CI:1.6%-100.0%)against death associated with COVID-19.The efficacy of full vaccination with revaccination against symptomatic cases of COVID-19 was 88.3%(95%CI:48.0%-99.6%).The overall mortality rate was higher in the unvaccinated group than in the vaccinated group(17.1%vs 3.0%;P=0.001).Higher Child-Turcotte-Pugh class cirrhosis(hazard ratio[HR]=4.13,95%CI:1.82-9.35)and higher age(HR=1.08,95%CI:1.04-1.15)were independent predictors of overall mortality,while vaccination had a protective effect(HR=0.09,95%CI:0.01-0.76).There was no significant difference in liver-related mortality(P=0.135)or the incidence of liver decompensation(P=0.077),bleeding esophageal varices(P=0.397),and vascular events(P=0.651)between the two groups of patients.CONCLUSION Vaccination against COVID-19 in patients with cirrhosis is effective and safe.

关 键 词：CORONAVIRUS VACCINATION REVACCINATION BOOSTER SARS-CoV-2 Sputnik V 

分 类 号：R575.2[医药卫生—消化系统] R186[医药卫生—内科学]